bortezomib,lenalidomide,dexamethasone,daratumumab
janssen,takeda
#mmsm #ims2022 griffin final analysis (dara-rvd vs rvd) phase ii, transplant eligible final analysis done after all pts completed at least 1 yr of f/u median f/u ~ 50 mo pfs improvement, no os diff, time to mrd -ve was shorter with dara-rvd 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities. No COI